Stefani Spranger
Overview
Explore the profile of Stefani Spranger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
9354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhandarkar V, Dinter T, Spranger S
Sci Immunol
. 2025 Jan;
10(103):eadf4726.
PMID: 39823318
Immune responses against cancer are dominated by T cell exhaustion and dysfunction. Recent advances have underscored the critical role of early priming interactions in establishing T cell fates. In this...
2.
Roerden M, Spranger S
Nat Rev Immunol
. 2025 Jan;
PMID: 39748116
Cancers can avoid immune-mediated elimination by acquiring traits that disrupt antitumour immunity. These mechanisms of immune evasion are selected and reinforced during tumour evolution under immune pressure. Some immunogenic subclones...
3.
Torres-Mejia E, Weng S, Whittaker C, Nguyen K, Duong E, Yim L, et al.
Cancer Immunol Res
. 2025 Jan;
PMID: 39745382
Tumor cell-intrinsic signaling pathways can drastically affect the tumor immune microenvironment, promoting tumor progression and resistance to immunotherapy by excluding immune-cell populations from the tumor. Several tumor cell-intrinsic pathways have...
4.
Roerden M, Castro A, Cui Y, Harake N, Kim B, Dye J, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39521615
Background: Intratumoral heterogeneity (ITH) and subclonal antigen expression blunt antitumor immunity and are associated with poor responses to immune-checkpoint blockade immunotherapy (ICB) in patients with cancer. The underlying mechanisms however...
5.
Leddy O, Cui Y, Ahn R, Stopfer L, Choe E, Kim D, et al.
Nat Protoc
. 2024 Oct;
PMID: 39438697
Vaccines and immunotherapies that target peptide-major histocompatibility complexes (peptide-MHCs) have the potential to address multiple unmet medical needs in cancer and infectious disease. Designing vaccines and immunotherapies to target peptide-MHCs...
6.
Morgan D, Horton B, Bhandarkar V, Van R, Dinter T, Zagorulya M, et al.
Sci Immunol
. 2024 Sep;
9(99):eadi3487.
PMID: 39270006
Immune checkpoint blockade (ICB) enhances T cell responses against cancer, leading to long-term survival in a fraction of patients. CD8 T cell differentiation in response to chronic antigen stimulation is...
7.
Mahat D, Kumra H, Castro S, Metcalf E, Nguyen K, Morisue R, et al.
bioRxiv
. 2024 Sep;
PMID: 39257788
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer without effective treatments. It is characterized by activating KRAS mutations and p53 alterations. However, how these mutations dysregulate cancer-cell-intrinsic gene programs to...
8.
Jazaeri A, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman R, et al.
Med
. 2023 Nov;
4(11):755-760.
PMID: 37951209
Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel...
9.
Horton B, DSouza A, Zagorulya M, McCreery C, Abhiraman G, Picton L, et al.
JCI Insight
. 2023 Sep;
8(19).
PMID: 37669107
Engineered cytokine-based approaches for immunotherapy of cancer are poised to enter the clinic, with IL-12 being at the forefront. However, little is known about potential mechanisms of resistance to cytokine...
10.
Nguyen K, Roerden M, Copeland C, Backlund C, Klop-Packel N, Remba T, et al.
Elife
. 2023 Aug;
12.
PMID: 37548358
Cancer immunotherapies, in particular checkpoint blockade immunotherapy (CBT), can induce control of cancer growth, with a fraction of patients experiencing durable responses. However, the majority of patients currently do not...